More than 10 million people around the world suffer from Parkinson's disease, according to the Parkinson's Disease Foundation. Unfortunately, pharmaceutical company Merck (MRK +1.65%) announced last week that it will halt the development of an experimental drug for this indication because of disappointing clinical data. Does Merck have other drugs in development for this disease? Are smaller biotechs making progress in this space? Health-care analyst Max Macaluso discusses these questions in the following video.
Clinical Trial Disappointment for This Pharmaceutical Giant
By Max Macaluso – Jun 1, 2013 at 9:00AM
NYSE: MRK
Merck
Market Cap
$214B
Today's Change
(1.65%) $1.39
Current Price
$85.78
Price as of November 6, 2025 at 4:00 PM ET
What does this mean for Merck going forward?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo